{"id":878,"date":"2025-11-24T12:12:45","date_gmt":"2025-11-24T12:12:45","guid":{"rendered":"https:\/\/rokote.com\/etusivu\/"},"modified":"2026-03-02T10:11:10","modified_gmt":"2026-03-02T10:11:10","slug":"etusivu","status":"publish","type":"page","link":"https:\/\/rokote.com\/fi\/","title":{"rendered":"Etusivu"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#0d336b&#8221; background_enable_image=&#8221;off&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;20px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;MONIK\u00c4YTT\u00d6INEN NEN\u00c4\u00c4N ANNETTAVA ROKOTEALUSTA INFEKTIOTAUTEJA VASTAAN&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|600||on|||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;70px&#8221; custom_margin=&#8221;40px|20px||20px|false|true&#8221; custom_margin_tablet=&#8221;|20px||20px|false|false&#8221; custom_margin_phone=&#8221;|20px||20px|false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; title_font_size_tablet=&#8221;75px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/rokotelabs-logowhite.gif&#8221; title_text=&#8221;rokotelabs-logo(white)&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; background_enable_image=&#8221;off&#8221; custom_margin=&#8221;40px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; border_width_bottom=&#8221;4px&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;20px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Osallistu tutkimukseen&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;15px|20px|5px|20px|false|true&#8221; custom_margin_tablet=&#8221;15px|20px|5px|20px|false|true&#8221; custom_margin_phone=&#8221;0px|20px|5px|20px|false|true&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; title_font_size_tablet=&#8221;80px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;Nen\u00e4sumutteena annettavan koronarokotteen kliiniseen l\u00e4\u00e4ketutkimukseen haetaan nyt vapaaehtoisia osallistujia.&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700|||||||&#8221; title_text_color=&#8221;#333333&#8243; title_font_size=&#8221;32px&#8221; custom_margin=&#8221;0px|20px|10px|20px|false|true&#8221; title_font_size_tablet=&#8221;50px&#8221; title_font_size_phone=&#8221;25px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_button button_url=&#8221;https:\/\/koronarokotetutkimus.fi\/&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;Lue lis\u00e4\u00e4 tutkimuksesta ja osallistumisesta&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;ab15fb74-61a3-43aa-96b3-41e09aeef654&#8243; custom_button=&#8221;on&#8221; button_text_size=&#8221;18px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#0d336b&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;100px&#8221; button_font=&#8221;Lato|900||on|||||&#8221; custom_margin=&#8221;20px|20px|50px|20px|false|true&#8221; custom_margin_tablet=&#8221;|20px||20px|false|true&#8221; custom_margin_phone=&#8221;0px||25px||false|true&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;12px|24px|12px|24px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; bottom_divider_style=&#8221;graph&#8221; bottom_divider_color=&#8221;#0d336b&#8221; bottom_divider_flip=&#8221;horizontal&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;FINVAC-rokoteteknologia&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;|20px|5px|20px|false|true&#8221; title_font_size_tablet=&#8221;80px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;Uuden sukupolven nen\u00e4\u00e4n annettavat rokotteet&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700|||||||&#8221; title_text_color=&#8221;#333333&#8243; title_font_size=&#8221;32px&#8221; custom_margin=&#8221;0px|20px|10px|20px|false|true&#8221; title_font_size_tablet=&#8221;50px&#8221; title_font_size_phone=&#8221;25px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; custom_margin=&#8221;|20px|0px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;]Rokote Laboratoriesin FINVAC-rokotealusta on suunniteltu monik\u00e4ytt\u00f6iseksi nen\u00e4\u00e4n annettavaksi rokoteteknologiaksi, jota voidaan nopeasti mukauttaa suojaamaan useita taudinaiheuttajia vastaan, kuten esimerkiksi SARS-CoV-2, influenssa, RSV, tuberkuloosi ja monet muut. Toisin kuin perinteiset lihakseen annettavat rokotteet, FINVAC-rokotteet annetaan nen\u00e4n limakalvolle, joka on hengitystieinfektioita aiheuttavien virusten ensisijainen sis\u00e4\u00e4nk\u00e4ynti elimist\u00f6\u00f6n. FINVAC-rokotteet aktivoivat sek\u00e4 paikallisen limakalvoimmuniteetin (IgA) ett\u00e4 systeemisen immuniteetin (IgG). <\/p>\n<p>Ensimm\u00e4inen FINVAC-rokotealustaa k\u00e4ytt\u00e4v\u00e4 rokote, FINVAC COVID-19, on nen\u00e4\u00e4n annettava SARS-CoV-2-rokote, joka on parhaillaan siirtym\u00e4ss\u00e4 toiseen kliiniseen tutkimukseensa<br \/>\n[\/et_pb_text][et_pb_toggle title=&#8221;Miksi intranasaalinen rokottaminen on t\u00e4rke\u00e4\u00e4&#8221; open_toggle_text_color=&#8221;#000000&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;25px&#8221; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;25px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#333333&#8243; title_font=&#8221;Lato||||||||&#8221; title_font_size=&#8221;30px&#8221; background_color=&#8221;#FFFFFF&#8221; title_font_size_tablet=&#8221;30px&#8221; title_font_size_phone=&#8221;25px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; border_width_all=&#8221;0px&#8221; global_colors_info=&#8221;{}&#8221;]Lihakseen annettavat rokotteet eiv\u00e4t yleens\u00e4 est\u00e4 tehokkaasti hengitystieinfektioita tai viruksen levi\u00e4mist\u00e4, koska ne saavat aikaan vain rajallisen limakalvoimmuniteetin ja edellytt\u00e4v\u00e4t siksi toistuvia tehosterokotuksia.<br \/>FINVAC-rokotteiden tavoitteena on ratkaista n\u00e4m\u00e4 haasteet aikaansaamalla voimakkaan nen\u00e4n limakalvon IgA-vasteen, joka avulla elimist\u00f6 neutraloi virukset jo niiden sis\u00e4\u00e4ntulokohdassa ja auttaa est\u00e4m\u00e4\u00e4n infektion, viruksen lis\u00e4\u00e4ntymisen ja siirtymisen muihin ihmisiin. <\/p>\n<p>&nbsp;<\/p>\n<h5>FINVAC-rokotealustan keskeiset ominaisuudet<\/h5>\n<ul>\n<li>Nopea mukautuvuus: Uudenlainen adenovirusvektorin runkorakenne mahdollistaa nopean p\u00e4ivitt\u00e4misen uusia virusvariantteja ja tulevia virusuhkia vastaan.<\/li>\n<li>Skaalautuva tuotanto: Valmistus perustuu patentoituun suspensiokasvatussolulinjaan, joka on optimoitu korkealaatuiseen, korkean saannon adenovirusvektorituotantoon.<\/li>\n<li>Uusi formulaatio: Eritt\u00e4in immunogeeninen rokotepuskuri, joka on parhaillaan kliinisess\u00e4 kehityksess\u00e4.<\/li>\n<li>Helppo annostelu: Nen\u00e4n kautta annettava yksinkertainen annostelu lis\u00e4\u00e4 hyv\u00e4ksytt\u00e4vyytt\u00e4 ja mahdollistaa itseannostelun, mik\u00e4 tekee FINVAC-rokotealustasta ihanteellisen massarokotuksiin ja haastaviin ymp\u00e4rist\u00f6ihin.<\/li>\n<\/ul>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/mikroskooppi-hoitaja-banner.jpg&#8221; title_text=&#8221;mikroskooppi-hoitaja-banner&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;|20px||20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; bottom_divider_style=&#8221;graph&#8221; bottom_divider_color=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/rokote_etusivu_1920x1280.jpg&#8221; title_text=&#8221;rokote_etusivu_1920x1280&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;|20px||20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Kehitett\u00e4v\u00e4t rokotteet&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;|20px|5px|20px|false|true&#8221; title_font_size_tablet=&#8221;80px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; custom_margin=&#8221;|20px|30px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;]FINVAC-rokotealustan ensimm\u00e4inen k\u00e4ytt\u00f6aihio on SARS-CoV-2-rokotteemme, jonka avulla osoitamme FINVAC-alustan potentiaalin universaalina nen\u00e4\u00e4n annettavana rokoteteknologiana.<br \/>\n[\/et_pb_text][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2026\/01\/siniset-nuolet-ja-teksti-suomenk-3.jpg&#8221; title_text=&#8221;tummansin_nuolet_rokote_eng&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;|20px||20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; bottom_divider_style=&#8221;graph&#8221; bottom_divider_color=&#8221;#0d336b&#8221; bottom_divider_flip=&#8221;horizontal&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Kliiniset tutkimukset&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;|20px|10px|20px|false|true&#8221; title_font_size_tablet=&#8221;80px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; custom_margin=&#8221;|20px|50px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>COV2FIN11 \u2013 Vaiheen I kliininen tutkimus<\/h2>\n<p>Rokote Laboratories on menestyksekk\u00e4\u00e4sti saanut p\u00e4\u00e4t\u00f6kseen ensimm\u00e4isen vaiheen I kliinisen tutkimuksen, jossa arvioitiin FINVAC COVID-19 -rokotteen turvallisuutta ja immuunivastetta kahdella eri annostelutavalla: nen\u00e4tippoina ja nen\u00e4suihkeena. Rokotteen immunogeenisuuden lis\u00e4analyysit ovat parhaillaan k\u00e4ynniss\u00e4.<\/p>\n<h2>COV2FIN12 \u2013 Vaiheen I kliininen tutkimus<\/h2>\n<p><strong>FINVAC COVID-19<\/strong> -rokotetta koskeva toinen vaiheen I kliininen tutkimus on suunniteltu alkavaksi tammikuussa 2026. Tutkimuksessa verrataan jo k\u00e4yt\u00f6ss\u00e4 olevaa rokotepuskuria kehitt\u00e4m\u00e4\u00e4mme uuteen, nen\u00e4annosteluun optimoituun FINVAC-rokotepuskuriin.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/doctor-asiakas-banneri-max.jpg&#8221; title_text=&#8221;doctor-asiakas-banneri-max&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;|20px||20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; bottom_divider_style=&#8221;graph&#8221; bottom_divider_color=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1440px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/rokote_uusi_etusivu.jpg&#8221; title_text=&#8221;rokote_uusi_etusivu&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;|20px||20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Rokote Laboratories Finland Oy&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;|20px|5px|20px|false|true&#8221; title_font_size_tablet=&#8221;80px&#8221; title_font_size_phone=&#8221;30px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; custom_margin=&#8221;|20px|30px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;]Rokote Laboratories on suomalainen bioteknologiayritys, joka perustettiin vuonna 2020 Helsingin ja It\u00e4-Suomen yliopistojen yhteisty\u00f6n tuloksena. Yritys kehitt\u00e4\u00e4 adenovirusvektoripohjaisia rokotteita, keskittyen nen\u00e4n kautta annettaviin ratkaisuihin ja limakalvoimmuniteetin vahvistamiseen. <\/p>\n<p>Missiomme on tehd\u00e4 rokottamisesta maailmanlaajuisesti turvallisempaa, helpompaa ja oikeudenmukaisempaa kehitt\u00e4m\u00e4ll\u00e4 edullisia, neulattomia nen\u00e4\u00e4n annettavia rokotteita, jotka auttavat est\u00e4m\u00e4\u00e4n tartunnan ja viruksen levi\u00e4misen toisiin ihmisiin.<br \/>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; top_divider_color=&#8221;#ca5c78&#8243; top_divider_flip=&#8221;horizontal|vertical&#8221; bottom_divider_style=&#8221;graph&#8221; bottom_divider_color=&#8221;#0d336b&#8221; bottom_divider_flip=&#8221;horizontal&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1400px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Uusimmat uutiset&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;0px|20px|40px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_blog fullwidth=&#8221;off&#8221; include_categories=&#8221;5&#8243; show_more=&#8221;on&#8221; show_author=&#8221;off&#8221; show_categories=&#8221;off&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;Lato||||||||&#8221; body_font=&#8221;Lato||||||||&#8221; read_more_font=&#8221;Lato|700|||||||&#8221; read_more_text_color=&#8221;#000000&#8243; custom_margin=&#8221;|20px||20px|false|true&#8221; custom_padding=&#8221;||40px||false|false&#8221; box_shadow_style=&#8221;preset1&#8243; box_shadow_color=&#8221;rgba(13,51,107,0.5)&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_blog][et_pb_button button_url=&#8221;https:\/\/rokote.com\/fi\/uutiset&#8221; button_text=&#8221;Kaikki uutiset&#8221; button_alignment=&#8221;left&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;ab15fb74-61a3-43aa-96b3-41e09aeef654&#8243; custom_button=&#8221;on&#8221; button_text_size=&#8221;14px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#0d336b&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;100px&#8221; button_font=&#8221;Lato|900||on|||||&#8221; custom_margin=&#8221;-50px|20px|50px|20px|false|true&#8221; custom_margin_tablet=&#8221;|20px||20px|false|true&#8221; custom_margin_phone=&#8221;||25px||false|true&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;12px|24px|12px|24px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1400px&#8221; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Tiimimme&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700||on|||||&#8221; title_text_color=&#8221;#0d336b&#8221; title_font_size=&#8221;42px&#8221; custom_margin=&#8221;|20px|70px|20px|false|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;Avainhenkil\u00f6st\u00f6&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|600|||||||&#8221; title_text_color=&#8221;#333333&#8243; title_font_size=&#8221;32px&#8221; custom_margin=&#8221;0px|20px|10px|20px|false|true&#8221; title_font_size_tablet=&#8221;50px&#8221; title_font_size_phone=&#8221;25px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_5,1_5,1_5,1_5,1_5&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;2560px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;-40px||-40px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/erkko_ylosmaki_mod.jpg&#8221; title_text=&#8221;erkko_ylosmaki_mod&#8221; url_new_window=&#8221;on&#8221; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; custom_margin=&#8221;||||false|false&#8221; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Erkko Yl\u00f6sm\u00e4ki&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\" style=\"text-align: center;\">FT, dosentti<br \/>Toimitusjohtaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<span style=\"color: #000000;\">Erkko Yl\u00f6sm\u00e4ki on virologian tohtori ja biologisen l\u00e4\u00e4kekehityksen dosentti, jolla on 20 vuoden kokemus uusien onkolyyttisten virusten sek\u00e4 sy\u00f6v\u00e4n immuunihoitojen kehitt\u00e4misest\u00e4. Vuonna 2019 h\u00e4n sai Vuoden Nuori Virologi -palkinnon Virustautien Tutkimuss\u00e4\u00e4ti\u00f6lt\u00e4. Ennen siirtymist\u00e4\u00e4n Rokote Laboratories Finland Oy:n palvelukseen h\u00e4n toimi Suomen Akatemian rahoituksella tutkijana professori Vincenzo Cerullon johtamassa immunoviroterapian laboratoriossa. H\u00e4n suoritti tohtorintutkintonsa virologian alalta Helsingin yliopiston l\u00e4\u00e4ketieteellisess\u00e4 tiedekunnassa vuonna 2013.   <\/span><br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/11\/Reunama_Terhi_mod.jpg&#8221; title_text=&#8221;Reunama_Terhi_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Terhi Reunama&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;13px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">Kliinisen tutkimuksen<br \/>johtaja<\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; custom_padding=&#8221;|||20px||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Terhi Reunama on kliinisen l\u00e4\u00e4ketutkimuksen asiantuntija, jolla on l\u00e4hes 30 vuoden kokemus niin l\u00e4\u00e4keteollisuudessa kuin CRO yrityksiss\u00e4. Koulutukseltaan h\u00e4n on sairaanhoitaja ja terveystieteiden kandidaatti, p\u00e4\u00e4aineena hoitotiede johtamisen koulutusohjelmassa. H\u00e4n on toiminut useissa rooleissa: tutkimushoitajana, CRA:na ja tutkimusp\u00e4\u00e4llikk\u00f6n\u00e4 sek\u00e4 paikallisella ett\u00e4 globaalilla tasolla I\u2013IV vaiheiden tutkimuksissa useilla eri terapia-alueilla, mukaan lukien rokotteet. Terhill\u00e4 on kokemusta monikultuuristen tiimien johtamisesta ja isoista monikeskustutkimuksista kaikilla mantereilla sek\u00e4 auditoinneista ja lukuisista viranomaistarkastuksista (mm. Fimea, FDA, MHRA, EMA).<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Tobias_Freitag_mod.jpg&#8221; title_text=&#8221;Tobias_Freitag_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Tobias Freitag&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">LT<br \/>Rokoteimmuniteettip\u00e4\u00e4llikk\u00f6<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\"><span style=\"color: #000000;\">Tobias Freitag on immunologi ja l\u00e4\u00e4ketieteen tutkija. H\u00e4n suoritti l\u00e4\u00e4ketieteen tohtorin tutkintonsa T\u00fcbingenin yliopistossa, ja on ty\u00f6skennellyt kliinisen gastroenterologian ja reumatologian osastoilla Erlangenin yliopistossa sek\u00e4 West Middlesexin yliopistollisessa sairaalassa Lontoossa. H\u00e4n suoritti jatkokoulutuksensa Detlef Schuppanin ryhm\u00e4ss\u00e4 gastroenterologian osastolla Beth Israel Deaconess Medical Centeriss\u00e4 Bostonissa sek\u00e4 Seppo Meren ryhm\u00e4ss\u00e4 Helsingin yliopiston Bakteriologian ja immunologian osastolla. Tobias Freitag on (limakalvon) immunologian, terapeuttisen immunomodulaation, rokoteimmuniteetin ja translaatiol\u00e4\u00e4ketieteen asiantuntija, ja h\u00e4n on hankkinut kokemusta useista julkisrahoitteisista sek\u00e4 teollisuuden rahoittamista akateemisista tutkimusprojekteista. H\u00e4n toimii yliopistotutkijana ja p\u00e4\u00e4tutkijana Helsingin yliopiston Bakteriologian ja immunologian osastolla.    <\/span><\/div>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Wallen-Tuula_mod.jpg&#8221; title_text=&#8221;Wallen-Tuula_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Tuula Wall\u00e9n&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">FM<br \/>Laatup\u00e4\u00e4llikk\u00f6<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Tuula Wall\u00e9n on toiminut yli 40 vuotta l\u00e4\u00e4keteollisuudessa erilaisissa teht\u00e4viss\u00e4 mm. markkinoinnissa, kliinisiss\u00e4 l\u00e4\u00e4ketutkimuksissa ja laadunvarmistuksessa farmaseuttisten tuotteiden, r\u00f6ntgenvarjoaineiden ja l\u00e4\u00e4kinn\u00e4llisten laitteiden parissa Suomessa ja pohjoismaisissa organisaatioissa. H\u00e4n on my\u00f6s toiminut kliinisten l\u00e4\u00e4ketutkimusten tutkimuskoordinaattorina, tutkimusp\u00e4\u00e4llikk\u00f6n\u00e4 ja laatup\u00e4\u00e4llikk\u00f6n\u00e4 sek\u00e4 tutkimuspalveluyrityksiss\u00e4 ett\u00e4 l\u00e4\u00e4ketehtaissa. Koulutukseltaan h\u00e4n on filosofian maisteri p\u00e4\u00e4aineenaan biokemia. Lis\u00e4ksi h\u00e4n on suorittanut markkinointitutkinnon.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Hellstrom-Kirsi_Full-resolution_Grey_mod.jpg&#8221; title_text=&#8221;Hellstrom-Kirsi_Full-resolution_Grey_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Kirsi Hellstr\u00f6m&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">FT, dosentti<br \/>CMC-asiantuntija<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Kirsi Hellstr\u00f6m on filosofian tohtori biotekniikan koulutusohjelmasta Jyv\u00e4skyl\u00e4n yliopistosta sek\u00e4 solu- ja molekyylibiologian dosentti Helsingin yliopistosta. H\u00e4n on ty\u00f6skennellyt sy\u00f6p\u00e4tutkimuksen parissa Teknologian tutkimuskeskus VTT Oy:n l\u00e4\u00e4ketieteellisen biotekniikan yksik\u00f6ss\u00e4 sek\u00e4 alfavirustutkijana Helsingin yliopistossa. Viimeksi h\u00e4n on ty\u00f6skennellyt Targovax Oy:ssa (nykyisin Circio Holding ASA) useissa eri CMC-teht\u00e4viss\u00e4, erityisesti onkolyyttisten adenovirusten tuotannossa ja toimitusketjuissa kliinisi\u00e4 tutkimuksia varten. H\u00e4n on toiminut my\u00f6s yrityksen vt. CMC-tiimin vet\u00e4j\u00e4n\u00e4 ja bioturvap\u00e4\u00e4llikk\u00f6n\u00e4.<br \/>\n[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_5,1_5,1_5,1_5,1_5&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;2560px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Rauhala_Nora_mod.jpg&#8221; title_text=&#8221;Rauhala_Nora_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Nora Rauhala&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\" style=\"text-align: center;\">Fil. yo<br \/>CRA<\/div>\n<div class=\"paragraph\" style=\"text-align: center;\"><\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\">Nora Rauhala on toiminut useita vuosia kliinisten tutkimusten parissa tutkimuskoordinaattorina (CRA) ja medical writer -teht\u00e4viss\u00e4. Teht\u00e4viin kuuluu mm. tutkimuslupien hakeminen, tutkimushenkil\u00f6st\u00f6n koulutus ja tutkimusten monitorointi tutkimuskeskuksessa. Lis\u00e4ksi h\u00e4n on kirjoittanut tutkimussuunnitelmia ja -raportteja. Nora Rauhala on filosofian maisteriopiskelija p\u00e4\u00e4aineena l\u00e4\u00e4ketieteellinen fysiikka.   <\/div>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Sammeli_Liikkanen_mod.jpg&#8221; title_text=&#8221;Sammeli_Liikkanen_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Sammeli Liikkanen&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\" style=\"text-align: center;\">\n<div class=\"paragraph\">PhD, eMBA,<\/div>\n<div class=\"paragraph\">Digital Medicine Advisor<\/div>\n<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Sammeli Liikkanen on Rokote Laboratories Finland Oy:n neuvonantaja kliinisen tutkimusohjelman digitalisoinnissa ja uusissa ratkaisuissa. H\u00e4nell\u00e4 on pitk\u00e4llinen kokemus l\u00e4\u00e4ketutkimuksesta ja -kehityksest\u00e4, sek\u00e4 l\u00e4\u00e4ketieteen ja terveydenhuollon digitalisaatiosta. Nykyisin h\u00e4n ty\u00f6skentelee Orionilla digitaalisen l\u00e4\u00e4ketieteen johtajana sek\u00e4 Orionin tutkimusekosysteemihankkeen vet\u00e4j\u00e4n\u00e4. H\u00e4n toimii t\u00e4m\u00e4n lis\u00e4ksi useiden digitaaliseen terveyteen liittyvien yritysten neuvonantajana.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;1400px&#8221; custom_margin=&#8221;||60px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Hallitus ja neuvonantajat&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato|700|||||||&#8221; title_text_color=&#8221;#333333&#8243; title_font_size=&#8221;32px&#8221; custom_margin=&#8221;0px|20px|10px|20px|false|true&#8221; title_font_size_tablet=&#8221;50px&#8221; title_font_size_phone=&#8221;25px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_5,1_5,1_5,1_5,1_5&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;2560px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;-39px|auto|-40px|auto|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/yla-herttuala_seppo_mod.jpg&#8221; title_text=&#8221;yla-herttuala_seppo_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; border_color_all=&#8221;#ca5c78&#8243; border_style_all=&#8221;dashed&#8221; global_colors_info=&#8221;{}&#8221; src__hover_enabled=&#8221;on|desktop&#8221; src__hover=&#8221;&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Seppo Yl\u00e4-Herttuala&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">LT, FT, akatemiaprofessori<br \/>Hallituksen puheenjohtaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_width_right=&#8221;0px&#8221; border_color_right=&#8221;#ca5c78&#8243; border_style_right=&#8221;dashed&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Seppo Yl\u00e4-Herttuala edustaa maailman k\u00e4rke\u00e4 syd\u00e4n- ja verisuonisairauksien sek\u00e4 aivo- ja virtsarakkokasvainten virusgeeniterapiassa. H\u00e4nen tutkimusryhm\u00e4ns\u00e4 oli ensimm\u00e4inen, joka k\u00e4ytti adenovirusta geeninsiirrossa ihmisen valtimoihin jo vuonna 1995. Sen j\u00e4lkeen h\u00e4n on suorittanut yhdeks\u00e4n faasien I\u2013III kliinist\u00e4 tutkimusta liittyen syd\u00e4n- ja verisuonisairauksien sek\u00e4 sy\u00f6v\u00e4n geeniterapiaan. H\u00e4n on my\u00f6s ollut vahvasti mukana uusien geeninsiirtovektoreiden kehitt\u00e4misess\u00e4 sek\u00e4 johtanut geeniterapiavalmisteiden suuren mittakaavan tuotantoprosessien kehityst\u00e4. H\u00e4n on toiminut Euroopan geeni- ja soluhoitoyhdistyksen puheenjohtajana vuosina 2010\u20132012 sek\u00e4 Amerikan geeni- ja soluhoitoyhdistyksen johtavan lehden Molecular Therapyn p\u00e4\u00e4toimittajana vuosina 2015\u20132019. T\u00e4ll\u00e4 hetkell\u00e4 h\u00e4n toimii kansallisen virusvektorilaboratorion johtajana It\u00e4-Suomen yliopistossa. H\u00e4n on yksi Rokote Laboratories Finland Oy:n alkuper\u00e4isist\u00e4 perustajista.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/kalle_saksela_mod.jpg&#8221; title_text=&#8221;kalle_saksela_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; border_color_right=&#8221;#ca5c78&#8243; border_style_right=&#8221;dashed&#8221; global_colors_info=&#8221;{}&#8221; src__hover_enabled=&#8221;on|desktop&#8221; src__hover=&#8221;&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Kalle Saksela&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">LT professori<br \/>Hallituksen j\u00e4sen<\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_width_right=&#8221;0px&#8221; border_color_right=&#8221;#ca5c78&#8243; border_style_right=&#8221;dashed&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Kalle Saksela on Helsingin yliopiston virologian professori ja virologian laitoksen johtaja. H\u00e4n suoritti l\u00e4\u00e4ketieteen lisensiaatin ja tohtorin tutkinnot Helsingin yliopistossa vuonna 1989, jonka j\u00e4lkeen h\u00e4n ty\u00f6skenteli tutkijatohtorina Yhdysvalloissa nobelisti David Baltimoren laboratoriossa Whitehead-instituutissa ja sittemmin Rockefellerin yliopistossa. Vuonna 1994 h\u00e4net nimitettiin apulaisprofessoriksi Rockefellerin yliopistoon. Vuonna 1996 h\u00e4net valittiin molekulaarisen l\u00e4\u00e4ketieteen professoriksi Tampereen yliopistoon ja vuonna 2005 nykyiseen toimeensa Helsingin yliopistoon. H\u00e4nell\u00e4 on vahva tausta molekulaarisessa solubiologiassa virusten ja is\u00e4nt\u00e4solujen v\u00e4lisen interaktion perustutkimuksessa sek\u00e4 soveltavan virologian tutkimuksessa, kuten bakteriofaagien avulla teht\u00e4v\u00e4ss\u00e4 proteiinien muokkauksessa sek\u00e4 virusvektoreiden kehitt\u00e4misess\u00e4 kliiniseen k\u00e4ytt\u00f6\u00f6n. H\u00e4n on useiden patenttien keksij\u00e4 sek\u00e4 ollut aktiivisesti mukana bioteknologian alan start-up-yrityksiss\u00e4. Kalle Saksela on yksi Rokote Laboratories Finland Oy:n alkuper\u00e4isist\u00e4 perustajista.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/aki_prihti_mod.jpg&#8221; title_text=&#8221;aki_prihti_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Aki Prihti&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">KTM<br \/>\u200bHallituksen j\u00e4sen<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Aki Prihti liittyi Rokote Laboratories Finland Oy:n hallitukseen kes\u00e4ll\u00e4 2021. H\u00e4n on Aplagon Oy:n toimitusjohtaja ja toimii Herantis Pharma Oyj:n, Medtentia International Ltd Oy:n sek\u00e4 Dassiet Oy:n hallituksen j\u00e4senen\u00e4. H\u00e4n on my\u00f6s yksi perustajista Inveni Capitalissa, joka on life science -yrityksiin keskittyv\u00e4 p\u00e4\u00e4omarahoittaja. H\u00e4nell\u00e4 on yli 20 vuoden kokemus life science -kasvuyritysten rakentamisesta sek\u00e4 operatiivisissa ett\u00e4 hallitusrooleissa.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/tuija_keinonen-mod.jpg&#8221; title_text=&#8221;tuija_keinonen-mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Tuija Keinonen&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">Fat), Hallituksen<br \/>ja johdon neuvonantaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Tuija Keinonen on farmakologiaan ja toksikologiaan suuntautunut farmasian tohtori It\u00e4-Suomen yliopistosta. H\u00e4nell\u00e4 on laaja kokemus yritysjohdosta, erityisesti tutkimuspalveluista ja niiden perustamisesta, sek\u00e4 ty\u00f6skentelyst\u00e4 kansainv\u00e4lisen l\u00e4\u00e4keteollisuuden kanssa. H\u00e4n on toiminut yli 30 vuotta palveluliiketoimintayrityksen (CRO) Oy Medfiles Ltd johdossa, josta toimitusjohtajana 15 vuotta, sek\u00e4 toiminut kliinisten tutkimusten johtajana, laatup\u00e4\u00e4llikk\u00f6n\u00e4 ja sopimusvalmistusyrityksen (CDMO) \u200bOy Medipharmia Ltd toimitusjohtajana. H\u00e4nell\u00e4 on useita yksityisen ja julkisen sektorin luottamustoimia sek\u00e4 yritysten hallitusj\u00e4senyyksi\u00e4 (mm. TILT Biotherapeutics Oy, jossa my\u00f6s hallituksen puheenjohtajuus). H\u00e4nell\u00e4 on hallitusty\u00f6skentelyn hyv\u00e4ksytty hallituksen j\u00e4sen (HHJ) ja hyv\u00e4ksytty hallituksen puheenjohtaja (HHJ PJ) -p\u00e4tevyydet. Lis\u00e4ksi h\u00e4n toimii useiden terveydenhuollon ja terveysteknologian yritysten neuvonantajana. H\u00e4n on toiminut my\u00f6s Viron kunniakonsulina vuodesta 2012 alkaen.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/kari_alitalo_mod.jpg&#8221; title_text=&#8221;kari_alitalo_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Kari Alitalo&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">LT, akatemiaprofessori<br \/>\u200bTieteellinen neuvonantaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\">Kari Alitalo on tieteen akateemikko. H\u00e4n on Wihurin tutkimuslaitoksen johtaja ja Helsingin yliopistossa Suomen Akatemian lippulaivan (iCAN) tieteellinen johtaja sek\u00e4 translationaalisen sy\u00f6p\u00e4l\u00e4\u00e4ketieteen tutkimusohjelman johtaja. Kari Alitalo on yksi Rokote Laboratories Finland Oy:n alkuper\u00e4isist\u00e4 perustajista.  <\/div>\n<p>[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_5,1_5,1_5,1_5,1_5&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;2560px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/pasi-kemppainen-mod.jpg&#8221; title_text=&#8221;pasi-kemppainen-mod&#8221; url_new_window=&#8221;on&#8221; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; custom_margin=&#8221;||||false|false&#8221; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Pasi Kemppainen&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">DI<br \/>Strateginen neuvonantaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Pasi Kemppainen on yksi Rokote Laboratories Finland Oy:n perustajista. H\u00e4nell\u00e4 on pitk\u00e4llinen kokemus aloittavista teknologiayrityksist\u00e4, ja h\u00e4n on toiminut johtoteht\u00e4viss\u00e4 life science- ja korkean teknologian yrityksiss\u00e4, kuten Santen Pharmaceutical, Novo Nordisk, Epista Life Science, Nokia ja Telia. Nykyisin h\u00e4n ty\u00f6skentelee Santen Pharmaceuticalilla maailmanlaajuisen toimitusketjun strategisena johtajana sek\u00e4 useiden korkean teknologian startup-yritysten neuvonantajana.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Kari_Varkila_mod.jpg&#8221; title_text=&#8221;Kari_Varkila_mod&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Kari Varkila&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">LKT, MBA<br \/>Kliinisenkehityksen neuvonantaja<\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]Kari Varkila on TILT Biotherapeutics Oy:n l\u00e4\u00e4ketieteellinen johtaja, ja h\u00e4n toimii my\u00f6s useiden terveydenhuollon ja terveysteknologian parissa ty\u00f6skentelevien yritysten ja terveydenhuoltoa ohjaavien organisaatioiden itsen\u00e4isen\u00e4 neuvontajana. H\u00e4n on suorittanut l\u00e4\u00e4ketieteen lisensiaatin, l\u00e4\u00e4ketieteen ja kirurgian tohtorin ja kliinisen mikrobiologian erikoisl\u00e4\u00e4k\u00e4rin tutkinnot Helsingin Yliopistossa sek\u00e4 MBA-tutkinnon Lausannen Yliopistossa\/IMD:ss\u00e4 Sveitsiss\u00e4. Lis\u00e4ksi h\u00e4nell\u00e4 on hallitusty\u00f6skentelyn HHJ-p\u00e4tevyys. Ty\u00f6uransa aikana h\u00e4n on toiminut Suomessa ja USAssa tutkimusty\u00f6ss\u00e4 akateemisessa ja kaupallisessa ymp\u00e4rist\u00f6ss\u00e4 ja l\u00e4\u00e4keteollisen tutkimuksen ett\u00e4 terveydenhuollon tuotannon johtoteht\u00e4viss\u00e4. Sen lis\u00e4ksi h\u00e4nell\u00e4 on johtotason ty\u00f6kokemusta vakuutusalalta, bioteknologian yrityksist\u00e4 ja konsultointiyrityksist\u00e4. Er\u00e4s h\u00e4nen erikoisosaamisalueistaan on rokotetutkimus ja -kehitys. H\u00e4n on my\u00f6s kokenut yhteiskuntavaikuttaja ja hallitusammattilainen, ja toimii nykyisin Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6n ja Wellmo Oy:n hallitusten j\u00e4senen\u00e4 sek\u00e4 Reumatautien tutkimuss\u00e4\u00e4ti\u00f6n hallituksen puheenjohtajana. Rokote Laboratories Finland Oy:ssa h\u00e4n toimii kliinisen kehityksen neuvonantajana.<br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Suoranta-Laura_mod.jpg&#8221; title_text=&#8221;Suoranta-Laura_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Laura Suoranta&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">DI<br \/>CMC-asiantuntija<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<span style=\"color: #000000;\">Laura Suoranta on Aalto-yliopiston Teknillisest\u00e4 korkeakoulusta valmistunut biotekniikan diplomi-insin\u00f6\u00f6ri. H\u00e4n on ty\u00f6skennellyt yli kymmenen vuoden ajan Targovax Oy:ss\u00e4 (aiemmin Oncos Therapeutics Oy, nykyisin Circio Holding ASA) useissa eri CMC-tiimin teht\u00e4viss\u00e4. Viime vuosina h\u00e4n on vastannut onkolyyttisten adenovirusten teollisen mittakaavan GMP-tuotantoprosessin pystytt\u00e4misest\u00e4 sek\u00e4 tuotantoprosessiin liittyv\u00e4n vertailtavuustutkimuksen suunnittelusta ja toteutuksesta. Sit\u00e4 ennen h\u00e4n on vastannut adenoviruksen GMP-tuotannosta faasien 1 ja 2 kliinisiin l\u00e4\u00e4ketutkimuksiin. Ennen uraansa virusvektoreiden parissa h\u00e4n on ty\u00f6skennellyt Teknologian tutkimuskeskus VTT Oy:n kasvibiotekniikan tutkimusryhm\u00e4ss\u00e4, miss\u00e4 h\u00e4n tutki mm. l\u00e4\u00e4keaineiden tuottamista kasvisolu- ja kudosviljelmiss\u00e4.    <\/span><br \/>\n[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;http:\/\/rokote.com\/wp-content\/uploads\/2025\/10\/Lehtivarjo_Anna-Kaisa_mod.jpg&#8221; title_text=&#8221;Lehtivarjo_Anna-Kaisa_mod&#8221; url_new_window=&#8221;on&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; border_radii=&#8221;off||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Anna-Kaisa Lehtivarjo&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Lato||||||||&#8221; title_text_align=&#8221;center&#8221; background_color=&#8221;#eeeeee&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Lato||||||||&#8221; text_font_size=&#8221;14px&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;20px|20px|20px|20px|true|true&#8221; border_width_right=&#8221;1px&#8221; border_color_right=&#8221;#d8d8d8&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div style=\"text-align: center;\">FM<br \/>Laatuneuvonantaja<\/div>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;BIO&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;Lato||||||||&#8221; border_color_bottom=&#8221;#0d336b&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"paragraph\">Anna-Kaisa Lehtivarjo on filosofian maisteri p\u00e4\u00e4aineenaan biotekniikka ja molekyylibiologia. H\u00e4nell\u00e4 on yli kymmenen vuoden kokemus laadunvarmistus- ja CMC regulatory affairs -teht\u00e4vist\u00e4 pitk\u00e4lle kehitetyss\u00e4 terapiassa k\u00e4ytett\u00e4vien l\u00e4\u00e4kkeiden (ATMP) teollisessa valmistuksessa. Anna-Kaisa on toiminut monenlaisissa laaturooleissa, kuten QP:na, Regulatory Affairs p\u00e4\u00e4llikk\u00f6n\u00e4 sek\u00e4 laatuyksik\u00f6n johtajana, ollen vastuussa tuotantolaitoksen laadunvarmistus-, laatuj\u00e4rjestelm\u00e4-, laadunvalvonta- ja ymp\u00e4rist\u00f6monitorointiyksik\u00f6ist\u00e4.  <\/div>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rokote Laboratoriesin FINVAC-rokotealusta on suunniteltu monik\u00e4ytt\u00f6iseksi nen\u00e4\u00e4n annettavaksi rokoteteknologiaksi, jota voidaan nopeasti mukauttaa suojaamaan useita taudinaiheuttajia vastaan, kuten esimerkiksi SARS-CoV-2, influenssa, RSV, tuberkuloosi ja monet muut. Toisin kuin perinteiset lihakseen annettavat rokotteet, FINVAC-rokotteet annetaan nen\u00e4n limakalvolle, joka on hengitystieinfektioita aiheuttavien virusten ensisijainen sis\u00e4\u00e4nk\u00e4ynti elimist\u00f6\u00f6n. FINVAC-rokotteet aktivoivat sek\u00e4 paikallisen limakalvoimmuniteetin (IgA) ett\u00e4 systeemisen immuniteetin (IgG). Ensimm\u00e4inen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-878","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/pages\/878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/comments?post=878"}],"version-history":[{"count":59,"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/pages\/878\/revisions"}],"predecessor-version":[{"id":1196,"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/pages\/878\/revisions\/1196"}],"wp:attachment":[{"href":"https:\/\/rokote.com\/fi\/wp-json\/wp\/v2\/media?parent=878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}